Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00544817 | Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme | completed | Phase 2 | 47 | SCRI Development Innovations, LLCOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT00302159 | Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2016 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT01331291 | Bosutinib in Adult Patients With Recurrent Glioblastoma | completed | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT02815410 | Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients | unknown | Phase 2 | 73 | Seoul National University HospitalOTHER | 0 | Jun 28, 2016 | clinicaltrials |
| NCT02060955 | Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan | terminated | Phase 2 | 25 | CytoVac A/SINDUSTRY | 1 | Jun 6, 2016 | clinicaltrials |
| NCT00267592 | Safety and Efficacy of Talampanel in Glioblastoma Multiforme | completed | Phase 2 | 72 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | May 19, 2016 | clinicaltrials |
| NCT01213407 | Dendritic Cell Cancer Vaccine for High-grade Glioma(GBM-Vax) | completed | Phase 2 | 87 | Activartis BiotechINDUSTRY | 1 | May 19, 2016 | clinicaltrials |
| NCT01445691 | More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery | withdrawn | Phase 2 | 0 | Constantinos HadjipanayisOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT02772094 | Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas) | unknown | Phase 2 | 50 | China Medical University HospitalOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT00445588 | Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2016 | clinicaltrials |
| NCT01847235 | Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial | completed | Phase 2 | 23 | Seoul National University HospitalOTHER | 1 | Apr 26, 2016 | clinicaltrials |
| NCT00995007 | A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas | completed | Phase 2 | 112 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2016 | clinicaltrials |
| NCT01351519 | A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors | terminated | Phase 2 | 16 | MultiCare Health System Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01474239 | A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma | completed | Phase 2 | 91 | Hoffmann-La RocheINDUSTRY | 1 | Mar 15, 2016 | clinicaltrials |
| NCT01466881 | Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 2 | Mar 10, 2016 | clinicaltrials |
| NCT00499473 | Sunitinib in Treating Patients With Recurrent Malignant Gliomas | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00085254 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 112 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00250211 | Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide | completed | Phase 1 / Phase 2 | 26 | AHS Cancer Control AlbertaOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT01663012 | Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma | completed | Phase 2 | 20 | Lawrence RechtOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT02430363 | Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 | unknown | Phase 1 / Phase 2 | 58 | Medical Research CouncilOTHER_GOV | 10 | Feb 24, 2016 | clinicaltrials |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT00301418 | Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma | completed | Phase 1 / Phase 2 | 11 | Northwell HealthOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT00310128 | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 0 | Feb 3, 2016 | clinicaltrials |
| NCT02663440 | Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme | unknown | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT01189240 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | terminated | Phase 1 / Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Dec 14, 2015 | clinicaltrials |
| NCT01113398 | AMG 102 and Avastin for Recurrent Malignant Glioma | completed | Phase 2 | 36 | Katy PetersOTHER | 1 | Dec 10, 2015 | clinicaltrials |
| NCT01260467 | Memantine for Recurrent Glioblastoma | terminated | Phase 2 | 4 | University of RochesterOTHER | 1 | Dec 10, 2015 | clinicaltrials |
| NCT02623231 | The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients(Cipralex&GBM) | unknown | Phase 2 / Phase 3 | 100 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00967330 | A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma | completed | Phase 2 | 182 | Hoffmann-La RocheINDUSTRY | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00116376 | Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) | completed | Phase 1 / Phase 2 | 64 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 10, 2015 | clinicaltrials |
| NCT02599090 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 6, 2015 | clinicaltrials |
| NCT00667394 | Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Nov 5, 2015 | clinicaltrials |
| NCT00846456 | Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma | completed | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 0 | Oct 20, 2015 | clinicaltrials |
| NCT01778530 | TRC105 for Recurrent Glioblastoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Oct 7, 2015 | clinicaltrials |
| NCT00369590 | VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00923117 | Sunitinib to Treat Recurrent Brain Cancer | terminated | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01898273 | Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma | terminated | Phase 2 | 7 | Cellectar Biosciences, Inc.INDUSTRY | 1 | Sep 9, 2015 | clinicaltrials |
| NCT00131937 | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2015 | clinicaltrials |
| NCT01462695 | Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 3 | Aug 27, 2015 | clinicaltrials |
| NCT01102595 | Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma | completed | Phase 2 | 102 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Aug 26, 2015 | clinicaltrials |
| NCT01227434 | A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma(PD0332991) | terminated | Phase 2 | 23 | University of California, San FranciscoOTHER | 1 | Jul 17, 2015 | clinicaltrials |
| NCT02474966 | Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study | completed | Phase 2 | 15 | University of Roma La SapienzaOTHER | 0 | Jun 18, 2015 | clinicaltrials |
| NCT01071837 | APG101 in Glioblastoma | completed | Phase 2 | 84 | Apogenix GmbHINDUSTRY | 2 | Jun 16, 2015 | clinicaltrials |
| NCT00112736 | Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2015 | clinicaltrials |
| NCT01174537 | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00004146 | Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | May 8, 2015 | clinicaltrials |
| NCT00004688 | Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms | completed | Phase 2 | 35 | Emory UniversityOTHER | 0 | Mar 25, 2015 | clinicaltrials |
| NCT01225510 | A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Mar 11, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2016source: clinicaltrials